FDA expands tamiflu use to treat babies under one year old
December 22, 2012 in Medications
Tamiflu can now be given to children as young as 2 weeks old under an expanded approval announced Friday by the U.S. Food and Drug Administration.
(HealthDay)—Tamiflu (oseltamivir) can now be given to children as young as 2 weeks old under an expanded approval announced Friday by the U.S. Food and Drug Administration.
Tamiflu can be used as treatment in children aged 2 weeks to 1 year if they have had flu symptoms for no longer than two days. The drug is not approved to prevent flu in these children and the safety and effectiveness of Tamiflu in children younger than 2 weeks of age has not been established.
While there are fixed dosing regimens for children 1 year and older according to weight categories, dosing for children younger than 1 year must be calculated individually based on exact weight, the FDA stressed. Children 2 weeks to 1 year of age should receive 3 milligrams per kilogram of weight twice daily for five days.
"Pharmacists must provide the proper dispenser when filling a prescription so parents can measure and administer the correct dose to their children," Edward Cox, M.D., M.P.H., director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, said in an FDA news release.
More information: More Information
Copyright © 2012 HealthDay. All rights reserved.
-
Tamiflu touted for child use
Nov 16, 2007 |
not rated yet |
0
-
FDA panel backs infant doses for kids' Tylenol
May 18, 2011 |
not rated yet |
0
-
FDA issues Tussionex safety alert
Mar 11, 2008 |
not rated yet |
0
-
Two pancreatic-enzyme products approved
Mar 02, 2012 |
not rated yet |
0
-
Children now eligible for screening test for bacterium
Feb 24, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
-
Marie Curie's leukemia
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
Acne pill benefits outweigh blood clot risk: EU agency
Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.
Medications
May 17, 2013 |
not rated yet |
0
First influenza vaccine brought to clinical testing
Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...
Medications
May 17, 2013 |
5 / 5 (1) |
0
Aspirin not always best treatment for many individuals
(Medical Xpress)—An aspirin a day may not always keep heart disease away, say two University of Florida cardiologists. But a new algorithm they have developed outlines factors physicians should weigh as ...
Medications
May 16, 2013 |
3.5 / 5 (2) |
0
|
FDA: lower ambien's dose to prevent drowsy driving
(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard ...
Medications
May 15, 2013 |
not rated yet |
0
Simponi approved for ulcerative colitis
(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.
Medications
May 15, 2013 |
not rated yet |
0
New theory on genesis of osteoarthritis comes with successful therapy in mice
Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...
Computational tool translates complex data into simplified 2-dimensional images
In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...
Researchers identify a potential new risk for sleep apnea: Asthma
Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...
Study finds that sleep apnea and Alzheimer's are linked
A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.
'Gap' for HIV vaccine efforts after latest setback
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
Ginger compounds may be effective in treating asthma symptoms
Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...
Dec 22, 2012
Rank: 3 / 5 (4)
Dec 23, 2012
Rank: 3.7 / 5 (3)
You got that right. Tamiflu is completely worthless, and does nothing to benefit adults, let alone children. The FDA is a criminal organization that should be ended.